Stifel analyst Alex Thompson raised the price target on Spyre (NASDAQ: SYRE) to $107.00 (from $92.00) while maintaining a Buy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Spyre Therapeutics, Inc. (SYRE) Misses Q1 EPS by 7cMay 5, 2026 10:20 AM Form 8-K Spyre Therapeutics, Inc. For: May 05May 5, 2026 8:05 AM Form 10-Q Spyre Therapeutics, Inc. For: Mar 31May 5, 2026 8:01 AM Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 5, 2026 8:00 AM Form 4 Spyre Therapeutics, Inc. For: May 01 Filed by: Burrows Scott LMay 1, 2026 9:35 PM Form 4 Spyre Therapeutics, Inc. For: May 01 Filed by: Sloan SheldonMay 1, 2026 9:35 PM Form 4 Spyre Therapeutics, Inc. For: May 01 Filed by: Turtle CameronMay 1, 2026 9:34 PM Form 144 Spyre Therapeutics, Inc. Filed by: Sloan SheldonMay 1, 2026 4:45 PM